Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

Journal of Neurosurgery - Tập 81 Số 2 - Trang 188-195 - 1994
Jon Glass1, Michael L. Gruber, Lawrence Cher, Fred H. Hochberg
1Brain Tumor Center, Temple University Cancer Center, Philadelphia, Pennsylvania.

Tóm tắt

✓ The treatment of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously fatal disease. Complete or partial responses to intravenous methotrexate (3.5 gm/sq m with leucovorin rescue every 3 weeks for two to four cycles) were seen in 12 of 13 patients originally treated. A total of 25 patients (including the original 13) have now been treated with one to six cycles of methotrexate every 10 to 21 days prior to WBRT. Twenty-two had partial or complete responses, with a median duration of response of 32 months. Median survival time was 33 months (42.5 months in those responding to therapy). Nine patients are alive and without evidence of disease 9 to 122 months following therapy. Acute and long-term toxicities were minimal. Systemic methotrexate administration prior to WBRT is well tolerated and produces long-term survival.

Từ khóa


Tài liệu tham khảo

Allen JC, 1980, Cancer Treat Rep, 64, 1261

Bernstein JI, 1986, J Clin Oncol, 4, 847, 10.1200/JCO.1986.4.6.847

Berry MP, 1981, Int J Radiat Oncol Biol Phys, 7, 55, 10.1016/0360-3016(81)90060-2

10.1016/S0936-6555(05)80738-1

Borsi JD, 1987, Cancer, 60, 5, 10.1002/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D

Brada M, 1990, Int J Radiat Oncol Biol Phys, 18, 787, 10.1016/0360-3016(90)90398-4

Chamberlain MC, 1990, Arch Neurol, 47, 1113, 10.1001/archneur.1990.00530100081017

Chamberlain MC, 1992, J Neurooncol, 14, 271, 10.1007/BF00172603

Cox DR, 1972, J R Stat Soc (B), 34, 187

DeAngelis LM, 1992, J Clin Oncol, 10, 635, 10.1200/JCO.1992.10.4.635

Ervin T, 1980, Cancer, 45, 1556, 10.1002/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B

10.1002/1097-0142(19860901)58:5<1106::AID-CNCR2820580521>3.0.CO;2-3

10.3171/jns.1989.70.2.0190

Glass J, 1993, Neurology, 43, A209

Gumerlock MK, 1990, Contemp Neurosurg, 12, 1, 10.1097/00029679-199012110-00001

10.1002/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P

10.3171/jns.1988.68.6.0835

Jellinger K, 1975, Acta Neuropathol Suppl, 6, 95

10.2307/2281868

Lachance DH, 1992, Neurology, 42, 343

Liang BC, 1992, Neurology, 42

Littman P, 1975, Cancer, 35, 1412, 10.1002/1097-0142(197505)35:5<1412::AID-CNCR2820350526>3.0.CO;2-T

Loeffler JS, 1985, J Clin Oncol, 3, 490, 10.1200/JCO.1985.3.4.490

Michalski JM, 1990, Radiology, 176, 855, 10.1148/radiology.176.3.2389047

10.3171/jns.1986.65.5.0600

10.1016/0360-3016(92)90538-S

Neuwelt EA, 1991, J Clin Oncol, 9, 1580, 10.1200/JCO.1991.9.9.1580

O'Neill BP, 1993, Ann Neurol, 34, 313

Pitman SW, 1977, Cancer Treat Rep, 61, 695

10.1002/1097-0142(19890301)63:5<939::AID-CNCR2820630526>3.0.CO;2-V

10.1002/1097-0142(19900501)65:9<1907::AID-CNCR2820650906>3.0.CO;2-L

Skarin AT, 1983, J Clin Oncol, 1, 91, 10.1200/JCO.1983.1.2.91

Skarin AT, 1977, Blood, 50, 1039

Turman S, 1977, Cancer, 40, 2823, 10.1002/1097-0142(197712)40:6<2823::AID-CNCR2820400612>3.0.CO;2-2

Thông tin
Thông tin xuất bản

Journal of Neurosurgery

Tập 81 Số 2

188-195

Thông tin tác giả